See if you recognize any of the faces found on the front cover of this MS Focus issue.
Please visit our MS learning channel on Youtube, which provides hundreds of topics from our education programs, that were video-recorded and archived here: www.youtube.com/msviewsandnews
-- Scroll left side of this blog for needed resources. Also, use our 'search by topic' tool, to find specific information.
Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.
Friday, May 21, 2010
See if you recognize any of the faces found on the front cover of this MS Focus issue.
Please explore our video library of MS Learn Online segments on this topic. Note that these videos are categorized into two types of segments. You may jump directly to your preferred segment type by clicking on one of the three links below.
Daily Minutes: Short informational clips about this topic, usually lasting around a minute or so.
Feature Presentations: More comprehensive coverage of a topic, usually featuring a variety of experts and/or perspectives. These are usually broken into 2-4 segments lasting 6-10 minutes each.
MS: A Family Adjustment
|Pregnancy and MS|
MS Learn Online is the National MS Society's online educational webcast series.
Transcripts (.pdf format) and podcasts (.mp3 audio format)
are available for most programs.
Current Feature Presentation
Clinical Trials: Solving One Piece
of the MS Puzzle
Sativex, a ground-breaking cannabis-based drug for treating symptoms of multiple sclerosis (MS), could be approved in the UK by the end of June, its creator said on Thursday.
A regulatory green light in Spain is expected shortly after, according to the company, which added that all major and minor issues relating to the application for Sativex's approval had been resolved.
The approval is now in its final stage, which involves finalising the wording on the product's packaging.
Sativex, which is sprayed under the tongue, is to be marketed in Britain by Germany's Bayer and in the rest of Europe by Spain's Almirall.
GW said both partners were well advanced in preparations for the Sativex launch and GW has manufactured stocks of Sativex for distribution immediately upon UK approval.
Thursday, May 20, 2010
The first symptom of MS occurred while I was in the services. These were optic neuritis and temporal-lobe epilepsy (TLE) or petit mal. I was sent to RAF Hospital, Ely, but doctors there at that time had insufficient information for any accurate diagnosis. Why were there dead cells floating in the vitreous humor? (I kept quiet about the TLE.)
In 1972 aged 36 I was initially diagnosed with MS by Dr Fred Lees at Colchester Hospital, Essex following a myelegram and a very painful lumbar puncture. The symptoms I had then included the usual "pins-and-needles" in my hands, feet and neck when I lowered my chin to chest (the well-known "Barber's chair syndrome"). I was referred to the National Hospital Queen Square, London for a second opinion. MS was confirmed! At the time I refused to believe it! Fay, the wife of a close friend, suffered from relapsing/remitting MS and I certainly didn't have the same symptoms suffered by her or by Jacqueline du Pré and I refused to believe it.
Sadly, in those days we PwMS received little support except what little we learned from books, the Internet, and other PwMS.
SNAKE Oil treatments - Feed on the Desperate, who seek medical cures. See how those with MS (and other diseases) are being lured into deceit of a cure
21st Century Snake Oil Part 1
May 18, 2010
British researchers report results of a Phase I safety/feasibility clinical trial involving six people with long-standing multiple sclerosis, testing intravenous injections of the patients’ own adult bone marrow cells containing a mix of stem cells. After one year, the investigators found the treatment safe, but because it was a small, open-label trial with no controls, they report that firm conclusions cannot be drawn about its effectiveness. The study, by Neil Scolding, MD (University of Bristol, United Kingdom) and colleagues, is published online on May 5, 2010 in Clinical Pharmacology & Therapeutics.
Background: MS involves immune attacks against the brain, spinal cord and other tissues that make up the central nervous system. For years, researchers have been investigating bone marrow transplantation as a way to reconstitute the immune system in people with aggressive MS whose immune cells have been purposely destroyed, in hopes of stopping the MS immune attacks. This approach is still being investigated as an experimental treatment of MS. Recent studies, largely involving animal models, have suggested that adult stem cells contained in the bone marrow might have the capacity to inhibit destructive immune activity and possibly stimulate tissue repair.
This Study: Six people who had had MS for a duration ranging from 9 to 20 years, and who had moderate to significant disability (scores on the EDSS disease activity scale ranging from 4.5 to 6.5), participated in the study over one year. Each participants’ own bone marrow cells were removed, then filtered and then infused into the vein. None required an overnight hospital stay for the procedure. Rather than separate out a specific type of bone marrow stem cell (such as mesenchymal cells that have received attention as possible repair cells), the research team determined there was sufficient evidence to suggest possible benefit of infusing a mix of whole bone marrow cells.
According to patient reports, they found the procedure tolerable, and no severe adverse events were reported. After the infusion, one participant had postoperative urinary retention, and two had a transient increase in lower limb spasticity. One participant had an MS relapse two months after the infusion.
Continue to read directly from the source of this article
Wednesday, May 19, 2010
AND HEAR PERSONAL STORIES
FROM OTHER PEOPLE WITH MS
If you are looking to learn more about MS therapies, the TYSABRI Hope and Health Teleconference Series may help you make a more informed treatment decision.
Many teleconference programs will be offered in 2010.
Log on to hear a physician discuss treatment information and to hear a panel of TYSABRI patients share their personal experiences. Ask them questions directly, or just listen to the discussion — all in the comfort of your own home.
Registration is easy — at no cost to you.
Sign up for free to learn more!
Simply call 1-866-644-8540 ten minutes before the start of each teleconference. When asked for a code, say, "Hope and Health Teleconference" — and you'll
For a complete listing of MS teleconferences and events in your area, visit www.TYSABRI.com.
TYSABRI is a prescription medicine approved for adult patients with relapsing forms of MS to slow the worsening of disability that is common in patients with MS and decrease the number of flare-ups (relapses). Because TYSABRI increases the risk of progressive multifocal leukoencephalopathy (PML), a rare brain infection that usually causes death or severe disability, TYSABRI is generally recommended for patients that have not been helped enough by, or cannot tolerate, another treatment for MS. TYSABRI does not cure MS and has not been studied for longer than two years or in patients with chronic progressive MS.
Tuesday, May 18, 2010
By Evra Taylor levy & Eddy Lang, Freelance
(article source see below)
In this article, read about MS, Dr. Zamboni's theory of and for the Liberation Treatment, and information on Zamboni's research
MONTREAL - Miracle cures are not a common occurrence but in the world of multiple sclerosis, the hopes of patients and their loved ones have never been as high as they are right now. The excitement stems from what is being touted as a circulation-improving surgical procedure that seems to promise remarkable results. With dramatic testimonials pitted against a skeptical scientific and regulatory community, the question is whether or not poor vein drainage from the head to the heart is a cause of MS and whether dilating the veins, known as "the liberation treatment," is helpful. We take a hard look at the evidence.
Monday, May 17, 2010
NESS L300 Foot Drop System
The NESS L300 is an advanced foot drop system designed to use mild stimulation to lift your foot to help you walk more safely and easily. If the NESS L300 is right for you, it may be easier to walk on flat ground, up and down stairs, as well as on uneven surfaces. This light-weight device is designed to fit just below your knee and to be put on and taken off with one hand. Use of the NESS L300 may eliminate the need to wear a rigid, heavy orthosis.
Is NESS L300 Right For Me?
Learn more about what conditions the NESS L300 may help and when it may not be appropriate to use it. Click here to learn more.
How NESS L300 WorksLearn how
the system works and explore it's unique design features. Click here to see how it works.
Learn the next step to trying the NESS L300. Click here to learn more.
Sunday, May 16, 2010
People living with MS may hold the key to curing this disease. One way they can make a difference is to arrange to donate their brain and spinal cord tissues when they die. The National MS Society supports three MS tissue banks, which are storage facilities that provide brain and spinal cord tissues to researchers studying multiple sclerosis. These studies generally focus on the pathology of MS — its nature, cause, and effects on the brain — and they are extremely important.
A tissue bank is very close to what it sounds like: an area in a laboratory or medical center where tissue specimens are "deposited" and stored for later "withdrawal" and use.
The MS tissue banks store brain and spinal cord tissues, spinal fluid, and other specimens from persons who had MS during their lifetimes. The banks are often interested in collecting specimens from people who do not have MS, or from family members. These samples are frozen or otherwise preserved very soon after the death of the donor. The banked tissues are carefully catalogued with information about the each donor's medical history.
For those considering donating tissue, planning ahead is essential. Brain tissue must be prepared within hours after death to be of use in research. (This donation need not interfere with funeral arrangements.)
The decision to contribute to this special type of research is most thoughtful, and is truly appreciated by all who are involved in moving toward a world free of MS.
Individuals interested in the possibility of tissue donation can contact these banks:
Click here to read the listings and article from the NMSS website